Carcinoma, Non-Small-Cell Lung: all 6,645 studies
Page 41 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.
- A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung CancerWithdrawnNCT04466917Phase 3
- Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWithdrawnNCT04464967Phase 1/2
- The Effect of a Combined Drainage Strategy in Uniportal Upper Lung LobectomyStatus unknownNCT04461652Not applicable
- A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain MetastasesWithdrawnNCT04460729Phase 2
- JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.Status unknownNCT04459663Phase 2
- Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）Status unknownNCT04459611Phase 2
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
- Multimodality Treatment Including Curative Resection of Advanced NSCLCStatus unknownNCT04455984
- Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.Status unknownNCT04453423Phase 2
- A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCompletedNCT04452214Phase 1
- The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to SurveillanceActive, not recruitingNCT04450043Not applicable
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive, not recruitingNCT04449874Phase 1
- Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung CancerStatus unknownNCT04448379Phase 1
- Evaluation of GLR2007 for Advanced Solid TumorsCompletedNCT04444427Phase 1/2
- Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer TreatmentStatus unknownNCT04440800
- A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid TumorsActive, not recruitingNCT04440735Phase 1/2
- A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung CancerStatus unknownNCT04439890Phase 3
- Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib TreatmentTerminatedNCT04438902Phase 2
- PD-L1 Expression in Cancer (PECan Study).Status unknownNCT04436406Not applicable
- A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung CancerTerminatedNCT04432207Phase 1
- Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II TrialActive, not recruitingNCT04432142
- A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLCWithdrawnNCT04430933Phase 1/2
- Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME StudyActive, not recruitingNCT04430725
- Immune Checkpoint Inhibitors and Atherosclerotic Plaque VolumeCompletedNCT04430712
- Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal CancerActive, not recruitingNCT04428905Phase 3
- Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung CancerStatus unknownNCT04427475Not applicable
- Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung CancerStatus unknownNCT04425681Phase 2
- A Study of DF6002 Alone and in Combination With NivolumabCompletedNCT04423029Phase 1
- Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung CancerTerminatedNCT04422392Phase 2
- JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway MutationsSuspendedNCT04418167Phase 1
- A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLCStatus unknownNCT04416035Phase 3
- X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesStatus unknownNCT04415320Phase 2
- A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid TumorsStatus unknownNCT04413227Phase 1
- AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLCActive, not recruitingNCT04413201Phase 4
- Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or MelanomaActive, not recruitingNCT04407247Phase 1/2
- Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLCStatus unknownNCT04405674Phase 2
- Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLCStatus unknownNCT04405661
- Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung CancerTerminatedNCT04405401Phase 2
- A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung CancerStatus unknownNCT04398940Phase 2
- Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung CancerStatus unknownNCT04397926Phase 1
- Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective StudyActive, not recruitingNCT04397432
- Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901Status unknownNCT04396457Phase 2
- First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2bTerminatedNCT04396340Phase 1
- A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneActive, not recruitingNCT04395677Phase 2
- A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04393883Not applicable
- Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker StudyActive, not recruitingNCT04392505Phase 2
- First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese SettingStatus unknownNCT04391283
- Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04384146Phase 1
- Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 InsertionsStatus unknownNCT04382300Phase 2
- Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Phase 3
- Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04379739Phase 2
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04379635Phase 3
- Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid TumorsCompletedNCT04374877Phase 1
- Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibStatus unknownNCT04358562Phase 2
- Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04356118Phase 4
- Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 InhibitorsStatus unknownNCT04355806
- Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for ChemotherapyCompletedNCT04351256Phase 2
- Lindera Obtusiloba for Non-small Cell Lung CancerCompletedNCT04348149Not applicable
- Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLCCompletedNCT04345146Phase 2
- Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsCompletedNCT04344795Phase 1
- The Canada Lymph Node Score Project: A Crossover TrialCompletedNCT04342377Phase 3
- An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain MetastasesStatus unknownNCT04339829Phase 2
- Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLCStatus unknownNCT04338620Phase 2
- Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR InhibitorsStatus unknownNCT04338243Phase 1/2
- Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLCStatus unknownNCT04331626Phase 4
- Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung CancerActive, not recruitingNCT04326153Phase 2
- A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone MetastasisStatus unknownNCT04325776Phase 2
- A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT04325763Phase 3
- eRAPID: Online Symptom Reporting in Lung CancerCompletedNCT04324437Not applicable
- Crizotinib in ALK Rearranged Non-small-cell Lung CancerStatus unknownNCT04317651
- Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib ResistanceStatus unknownNCT04316351Phase 2
- National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
- Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)CompletedNCT04314089Phase 1
- A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC PatientsCompletedNCT04312308
- A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT04311034Phase 1/2
- Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsActive, not recruitingNCT04310020Phase 2
- Texture Features and PDL1 in CT-PET 18 FDGCompletedNCT04309422
- A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung CancerStatus unknownNCT04306926Phase 2
- Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLCStatus unknownNCT04304638
- Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung CancerActive, not recruitingNCT04304248Phase 2
- Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLCStatus unknownNCT04303130Phase 2
- A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or RecurrenceCompletedNCT04298606Early Phase 1
- Bioimaging Study of 89Zr-M7824 in NSCLCTerminatedNCT04297748Phase 1/2
- A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerCompletedNCT04294810Phase 3
- Why in Hospital After VATS LobectomyCompletedNCT04294108
- Tumor Mutational Burden in Lung Cancer PatientsTerminatedNCT04289259
- Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT04285671Phase 1/2
- PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLCStatus unknownNCT04284202Phase 2
- A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsTerminatedNCT04278144Phase 1/2
- Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung CancerStatus unknownNCT04275687Phase 2
- A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) ExpressionTerminatedNCT04274907Phase 1
- A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 TabletsStatus unknownNCT04273815Phase 1/2
- A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated CancersTerminatedNCT04272203Phase 1
- Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung CancerCompletedNCT04271384Phase 2
- Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)Active, not recruitingNCT04268550Phase 2
- A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung CancerWithdrawnNCT04267237Phase 2
- Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung CancerCompletedNCT04266691
- Cancer Genome Atlas of China:Lung CancerStatus unknownNCT04266483
- KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCTerminatedNCT04265534Phase 2
- Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural EffusionStatus unknownNCT04263688